David Sharek

David Sharek is stock portfolio manager at Shareks Stock Portfolios and the founder of The School of Hard Stocks. David's posted four years of +40% returns in his 16 year career. His Growth Portfolio has averaged investors 13% per year since 2003, 5% better than the S&P 500's 8% during that time. His book The School of Hard Stocks can be found on Amazon.com.

Is Celgene Now a Value Stock?

Biotech drug company Celgene (CELG) has lost around half its value since last Fall. At this point, is the stock a good value?

JPMorgan has an Easy Working Environment

JPMorgan (JPM) achieved broad-based gains throughout its major divisions last qtr. With Trump boosting the economy & raising interest rates, JPM has an easy working environment.

UnitedHealth’s Results Continue to Shine

UnitedHealth (UNH) has beaten the street, upped estimates, and delivered at least 23% profit growth the last 7 qtrs. And along the way the stock has continued to shine.

Visa Has Really Been a Perfect Stock

Since going public back in 2008, VIsa (V) has really been a perfect stock. Profits have grown each year as revenues climbed steadily. But if you’re looking for a discount forget it.

Trump’s Economy is Good News for Grainger

Trump’s economic plan has put a charge into sales and profit growth at industrial supply chain Grainger (GWW) as large and midsized customers are buying more goods.

Higher Rates, Higher Dollar Hurting 3M

Shares of 3M (MMM) broke their uptrend last qtr as higher interest rates and a stronger dollar have made the shares less valuable in my eyes.